HematologyNews.net

Hematology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Mediexplorer.it

Search results for "MabThera"

A phase II trial, led by John D. Hainsworth of the Sarah Cannon Cancer Center and Tennessee Oncology, Nashville , evaluated the efficacy of Rituximab ( MabThera, Rituxan ) with short-duration chemoth ...


In studies with mice, treatment with a new monoclonal antibody that targets immune system B cells has shown considerable promise for treating leukemias, autoimmune diseases and transplant rejection. ...


Statins, drugs widely prescribed to lower cholesterol, do not interfere with a commonly used medication to treat lymphomas, according to a study presented at the 50th Annual Meeting of the American So ...


Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of ...


Radioimmunotherapy with the radioactive drug Yttrium-90 ( 90Y ) Ibritumomab tiuxetan ( Zevalin ), following chemotherapy with Fludarabine ( Fludara ) and Mitoxantrone ( Novantrone ), is feasible, well ...


Novel treatments have shown improvements in survival and response rates for leukemia and lymphoma. The use of Dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the ...


Radioimmunotherapy with the radioactive drug Yttrium-90 ( 90Y ) Ibritumomab tiuxetan ( Zevalin ), following chemotherapy with Fludarabine ( Fludara ) and Mitoxantrone ( Novantrone ), is feasible, well ...


A phase III study is the first to prospectively determine that adding Rituximab ( MabThera, Rituxan ) to Dexamethasone is safe and effective in adult patients with previously untreated idiopathic thro ...


Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of ...


Statins, drugs widely prescribed to lower cholesterol, do not interfere with a commonly used medication to treat lymphomas, according to a study presented at the 50th Annual Meeting of the American ...


A new study has found for the first time that maintenance therapy with the novel antibody, Rituximab ( MabThera, Rituxan ) following Cyclophosphamide, Vincristine and Prednisone ( CVP ) therapy improv ...


A new analysis has concluded that Rituximab ( MabThera, Rituxan ), a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of ...


The first results from CLL11, a phase III study of the investigational medicine Obinutuzumab ( GA101; Gazyva ) were presented. The CLL11 study compared the combination of either GA101 or Rituximab ( M ...


Results from a phase 2 study ( Study 101-08 ) evaluating Idelalisib ( formerly GS-1101 ), an investigational, targeted, oral inhibitor of PI3K delta, in combination with Rituximab ( MabThera, Rituxan ...


Rituximab ( MabThera, Rituxan ) plus chemotherapy, most often CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone ), is the first-line standard of care for patients with advanced indolen ...